Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MSP3 Biofusion
- Development stage
- Unknown
- Lead developer
- Vac4All
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
01
Overview
MSP3 Biofusion is a second-generation malaria vaccine developed by Vac4All, designed to target the Merozoite Surface Protein 3 (MSP3) antigen on Plasmodium falciparum parasites during the blood stage of infection. As part of the ADAMVAX (antibody-dependent anti-malaria vaccines) platform, this biofusion protein vaccine is engineered to be 20-100 fold more potent at inducing correlates of protection compared to the first-generation MSP3-LSP vaccine. It works by eliciting antibodies that target the asexual, disease-causing stages of the parasite, providing protection against clinical malaria. The vaccine is currently in Phase 1/2b clinical development.
- Other names
- MSP3-BiofusionMSP-3-BiofusionMSP 3-BiofusionVac4All-MSP3Vac-4All-MSP3Vac 4All-MSP3
02
Targets
MSP3 (Plasmodium falciparum merozoite surface protein 3)
Beyond the preview
Go deeper on MSP3 Biofusion.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MSP3 Biofusion.